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Abstract
Purpose To assess whether comprehensive medication re-
views conducted by clinical pharmacists as part of a healthcare
team reduce drug-related hospital readmission rates among
people with dementia or cognitive impairment.
Methods This randomized controlled trial was carried out be-
tween January 9, 2012, and December 2, 2014. Patients aged
≥65 years with dementia or cognitive impairment admitted to
three wards at two hospitals located in Northern Sweden were
included.
Results Of the 473 deemed eligible for participation, 230 were
randomized to intervention and 230 to control group by block
randomization. The primary outcome, risk of drug-related
hospital readmissions, was assessed at 180 days of follow-up
by intention-to-treat analysis.
During the 180 days of follow-up, 18.9% (40/212) of pa-
tients in the intervention group and 23.0% (50/217) of those in
the control group were readmitted for drug-related reasons
(HR = 0.80, 95% CI = 0.53–1.21, p = 0.28, univariable Cox
regression). Heart failure was significantly more common in
the intervention group. After adjustment for heart failure as a
potential confounder and an interaction term, multiple Cox
regression analysis indicated that pharmacist participation
significantly reduced the risk of drug-related readmissions
(HR = 0.49, 95% CI = 0.27–0.90, p = 0.02). A post-hoc
analysis showed a significantly reduced risk of 30-day
readmissions due to drug-related problems in the total sample
(without adjustment for heart failure).
Conclusion Participation of clinical pharmacists in healthcare
team conducting comprehensive medication reviews did not
significantly reduce the risk of drug-related readmissions in
patients with dementia or cognitive impairment; however,
post-hoc and subgroup analyses indicated significant effects
favoring the intervention. More research is needed. Trial reg-
istration: Clinical trials NCT01504672.
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Introduction
Age-related changes such as renal impairment, comorbidities,
and subsequent polypharmacy as well as drug-drug interac-
tions pose challenges to appropriate pharmacotherapy in old
people. Problems associated with drug treatment such as poor
adherence, medication errors, and adverse drug events are
common. Up to 30% of hospital admissions are related to
drug-related problems (DRPs) among old people [1, 2] and
an even higher proportion is seen among people with demen-
tia [3]. Adverse drug reactions (ADRs), inappropriate drug
use, drug-drug interactions, overprescription, or lack of re-
quired medication are contributing to drug-related hospital
admissions [4]. Moreover, according to one meta-analysis,
up to 24% of patients develop adverse drug reactions during
their hospital stay [5].
Old people with dementia are particularly vulnerable to
adverse drug reactions. A potential cause could be reduced
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acetylcholine levels in the brain compared to healthy individ-
uals [6, 7]. Drug prescriptions are often not adapted to the
special demands of patients with dementia [8]. Several studies
indicate that use of potentially inappropriate drugs is common
among this group of people [9, 10] despite the increased risk
of adverse drug reactions and hospital admissions [11].
However, a high proportion of drug-related hospital admis-
sions is preventable [12]. Often, multiple disciplines and
specialties are involved in patient treatment with ill-
defined distribution of responsibilities for the overall
drug management. Participation of a clinical pharmacist
in the multidisciplinary hospital ward team could ensure
a more coherent pharmacotherapeutic approach across
the traditional borders of medical specialities and there-
by reduce the risk of DRPs [13].
Recent systematic reviews suggest that interventions by
clinical pharmacists can improve patient outcomes in both
inpatient and outpatient care facilities [14–17]. However, the
results are inconsistent whether pharmacist interventions can
reduce hospital readmissions and mortality [18]. In many
countries such as the USA, clinical pharmacists have been a
natural part of the multiprofessional health care teams for
many years [19].
To the best of our knowledge, the effectiveness of clinical
pharmacist participation in a ward team on the risk of hospital
readmissions in individuals with dementia or cognitive im-
pairment has yet not been studied. The aim of the present
study is to assess whether comprehensive medication reviews
conducted by clinical pharmacists as members of a ward team
could reduce the rate of drug-related hospital readmissions
among old people with dementia or cognitive impairment.
Methods
Study design, setting, and participants
A randomized controlled study design was used to compare
hospitalized patients obtaining usual care with those receiving
additional standardized medication reviews performed by an
experienced clinical pharmacist. Patients admitted to acute
internal medicine wards at the Skellefteå County Hospital
(n = 108) and Umeå University Hospital (n = 290) and to
the orthopedic ward at Umeå University Hospital (n = 62)
were included. These were selected on the basis of being the
wards where the clinical pharmacists already worked at study
start. Both hospitals are located in Northern Sweden.
Eligible patients were aged 65 years or older and had de-
mentia or cognitive impairment. Medical records were care-
fully reviewed before inclusion to avoid the risk of including
people without dementia or cognitive impairment. Dementia
diagnoses were collected from the medical records. Patients
were considered to have cognitive impairment if sufficient
information in the medical record related to memory, orienta-
tion, or executive function was noted before index hospitali-
zation. In addition, patients in whom dementia was suspected
and medical investigation had been commenced or would be
initialized were included. In ambiguous or uncertain cases,
patients were excluded.
Ethical approval
In Sweden, the Ethical Review Law permits research involv-
ing persons with cognitive impairment under certain condi-
tions, even though they cannot give a full informed consent.
The procedure still should be as Binformed consent-like^ as
possible taking into account the cognitive level of the persons.
The permission for the present study was sought and approved
for research without consent in accordance with the Swedish
Ethical Review Law (Regional Ethical Review Board in
Umeå, Sweden, registration number 2011-148-31M).
Research person and their next of kin were given written
and orally presented information about the research, individ-
ually adjusted to their cognitive level, and persons who did not
wish to participate were able to decline or withdraw from the
study.
Randomization and masking
The patients were randomly assigned to one of two groups:
intervention group or control group. The randomization se-
quence was prepared before study start using a throwing
dice—method by an independent person who was not en-
gaged in the trial in any other way. The sequence was per-
formed in blocks of 6–36 (each block contained between 3
and 18 intervention allocations and the same number of con-
trol allocations). Randomization was stratified at ward level.
To accomplish this, each ward used their own randomization
blocks, consecutively starting a new block after completion of
the preceding, meaning that there were an equal number of
control and intervention participants in each ward.
When a patient formally entered the trial, an employee of
the Department of Pharmacology and Clinical Neuroscience
who was not involved in the interventions provided the treat-
ment allocation according to the randomization scheme. The
patients and pharmacists were not blinded to treatment
assignment.
Intervention
Three clinical pharmacists with post-graduate degrees in clin-
ical pharmacy and long experience in performing medication
reviews in primary care and hospital wards conducted the
interventions. The pharmacists were already part of the differ-
ent ward teams at the time when the study started. The addi-
tional service provided by the clinical pharmacists consisted
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of medication reconciliation, medication review, and partici-
pation in ward rounds. The three clinical pharmacists met
continuously throughout the study period and discussed inter-
ventions to harmonize the advices given during ward rounds.
By conducting medication reconciliation, the pharmacists
ensured that the medication administration records used at the
wards were updated, accurate, and complete. Various infor-
mation sources were used, including drug lists from primary
care centers, the patients’ hospital medical records, and in two
cases, interviews with patients and/or relatives.
Based on an updated drug list, a comprehensive medication
review was performed by the clinical pharmacist comprising
aspects associated with the patients’ drug therapy, including
the medication list, list of laboratory results, medical record
notes from primary care and index admission, and also notes
from earlier contacts with healthcare providers, to compile an
extensive medication history. In addition, general data regard-
ing age, gender, and patient history were collected. All data
were recorded on a patient-specific documentation sheet. The
clinical pharmacists identified relevant DRPs with respect to
impairment of body function (renal function, liver function,
contraindications, allergies, swallowing problems), certain
drug use (toxic drugs, drugs prone to produce side effect,
potentially inappropriate drugs), interactions (drug-drug, and
drug-food), symptoms (adverse drug reactions), and general
judgment of the patient’s drug use (proper drug selection,
dosage, duration of treatment, polypharmacy, indication for
therapy, untreated indication, adherence, over-the-counter
drugs, and effectiveness). Clinical response to drug treatment
was monitored throughout the hospital stay.
The clinical pharmacist participated in ward rounds, and
clinically relevant DRPs were discussed with the healthcare
team (physicians, nurses, enrolled nurses). Advice was given
about drug selection, dosages, and possible monitoring needs.
The attending physicians made the final decision concerning
proposed changes to therapy. The acceptance or rejection of
the pharmacist’s recommendation for changes in drug therapy
was documented. All DRPs were recorded on a standardized
form and classified according to Cipolle et al. [20] into seven
categories: unnecessary drug therapy, needs additional drug
therapy, ineffective drug, dosage too low, dosage too high,
adverse drug reactions, and non-adherence. The follow-up
time was 180 days after discharge from index admission.
Outcomes
To assess the primary outcome, risk of drug-related
readmissions, data were collected from electronic medical re-
cords during the first 180 days after discharge from index
admission. An independent, blinded external expert group
consisting of one specialist in geriatrics, one specialist in in-
ternal medicine, and one clinical pharmacist working in an-
other county assessed the outcomes. For each participant, the
expert group received the drug list, laboratory list, doctors’
notes, and epicrisis from the first admission and from any
readmission(s). Data were copied from the medical records
and carefully reviewed twice to make sure anything that could
reveal group assignment was deleted. Before handed to the
experts, data were also anonymized.
The expert group decided whether the readmissions were to
be considered drug-related or not. They were instructed to
focus on all sorts of problems concerning drug treatment,
i.e., problems actually caused by a prescribed drug, but also
problems with not having a drug prescribed or adherence
problems. Discordant judgments were referred for consensus
discussions in the whole expert group to reach a decision. In
those cases where obvious suspected drug-related problems
were found by the clinical pharmacists, the information were
given back to the expert group for a second valuation (still
blinded). The likelihood that readmissions were drug-related
was graded into categories certain, probable, possible, or un-
likely/un-assessable, in accordance with the World Health
Organization (WHO) criteria for causality assessment of
ADR [21]. Later, in statistical analysis, readmissions classified
as certain, probable, and possible were grouped as Bdrug-
related^, the remaining as Bnon-drug-related^. A secondary
outcome parameter was Ball-cause^ readmission. At the time
the study was planned in 2011, a follow-up period of 180 days
for hospital readmissions was considered adequate. However,
in late 2012, the hospital readmission reduction program was
launched in the USA and England restricting payments for
early readmissions within 30 days of discharge from a previ-
ous (index) admission [22]. Consequently, we also evaluated
short-term effects of the intervention (readmissions within
30 days) in a post-hoc analysis. Secondary outcomes included
cost analysis, time to institutionalization, and adherence to
quality indicators (not yet analyzed).
Statistical analyses
We calculated that a sample size of 460 patients would provide
80% power to detect a 20% reduction in readmissions attrib-
uted to the participation of a clinical pharmacist. An intention-
to-treat analysis was performed, including all participants ex-
cept those who died during the hospital stay before discharge
(no follow-up time). For analysis of the primary outcome pa-
rameter, a Cox regression model was used.
There was a significant difference in the prevalence of heart
failure between the intervention and control group. Heart fail-
ure had a significant impact on the risk of readmission, and
furthermore, the intervention did not have any effect among
those with heart failure. These confounding and interaction
effects were accounted for by including a heart failure and
an interaction term between Bintervention^ and Bheart failure^
in the final model.
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First-time drug-related readmissions after index discharge
were summarized in Kaplan-Meier curves separately for the
intervention and the control group applying a log rank test.
Dichotomous variables were analyzed using the Pearson chi-
square test and continuous variables using the independent
sample t test. Differences between the groups for the number
of readmissions were analyzed applying the Mann-WhitneyU
test. IBM SPSS Statistics package v.22.0 was used for statis-
tical analyses. We regarded p values of 0.05 or less to be
statistically significant.
Results
Between January 9, 2012, and December 2, 2014, 473 patients
aged 65 years or older were invited to participate in the trial.
Thirteen subjects declined participation. The remaining 460
patients were randomized (230 to the intervention group and
230 to the control group). One individual in the control group
used the right to withdraw from the trial before discharge. In
addition, 31 patients (18 in intervention and 13 in control) died
before discharge. These 31 individuals were excluded from
the analysis, leaving a final sample of 429 patients. Figure 1
illustrates the patient flow throughout the trial. No significant
differences between the intervention and control group were
found for the majority of baseline characteristics. However,
significantly more patients in the intervention group had a
history of heart failure compared to the control group (34 vs
25%, p = 0.04) (Table 1).
The clinical pharmacists identified at least one DRP in 66%
(140/212) of individuals in the intervention group, summing
up for a total of 310 DRPs. The doctors followed the advice of
the clinical pharmacists in 82% of the identified DRPs (74%
of proposed actions were already effectuated during the hos-
pital stay while 8% were issued as written recommendations
in the discharge notes addressed to the general practitioners).
Actions taken to the suggested DRPs were discontinuation of
drug therapy (n = 78), followed by reduction in dosage
(n = 45) and correction of transition errors (n = 22).
Initiation of drug therapy (n = 21), change of drug (n = 19),
monitoring of laboratory values (n = 13), increase in dosage
(n = 8), and change of drug formulation (n = 4) were other
actions taken for the clinical pharmacists’ suggestions.
Further, 20 actions taken were categorized as Bother^, 24 sug-
gestions were written in discharge notes, and 56 of the sug-
gestions were rejected.
The DRPs were classified as follows: ADR (n = 103), in-
effective drug/inappropriate drug (n = 54), unnecessary drug
therapy (n = 54), dosage too high (n = 44), needs additional
drug therapy (n = 37), dosage too low (n = 14), and non-
adherence (n = 4). The time spent on performing a medication
review was on average 32 min per patient (range 10–90 min).
Approximately 20 min per patient was spent in ward rounds,
and it took 10 min for the clinical pharmacists to walk to the
ward and back, in total, 62 min.
The frequenciesof readmissionsanddeathsduring the180days
of follow-upafterdischargeare summarized inTable2.During this
period, 18.9% (40/212) of patients in the intervention group and
23.0%(50/217)ofpatients in thecontrolgroupwere readmitted for
473 patients assessed for eligibility
13 Excluded
13 declined to 
participate 
460 randomized
230 allocated to 
intervention
230 allocated to 
control




13 died before discharge 
216 included in 
analysis
212 included in 
analysis




18 died before discharge 
1 discontinued 
1 withdrew consent before 
discharge
Fig. 1 Patient flow chart
throughout the study
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drug-related reasons (HR 0.80, 95% CI 0.53–1.21, p = 0.28,
univariable Cox regression). A Kaplan-Meier survival analysis
showed no significant difference in time-to-drug-related readmis-
sion within 180 days between the intervention and control groups
(160.0 (standard deviation 3.3) days vs 150.1 (4.0) days, Mantel-
Cox log rank test,p=0.28) (Fig. 2).Heart failurewas significantly
more common in the interventiongroup (p=0.04) andwas associ-
atedwith an increased risk of drug-related readmissions (HR2.48,
95% CI 1.64–3.76, p < 0.001). Pharmacist intervention had no
impact on drug-related readmissions among patients with heart
Table 1 Baseline characteristics
of participants randomized to
control or intervention groups
Control (n = 217) Intervention (n = 212) p value
Women 138 (64%) 133 (63%) 0.854
Age, mean (SD), years 83.1 (6.6) 83.1 (6.6) 0.996
Laboratory values
Sodium level, mean (SD), mmol/L 139.1 (4.1) 138.9 (5.1) 0.568
Potassium level, mean (SD), mmol/L 4.1 (0.5) 4.1 (0.5) 0.774
Hb, mean (SD), g/L 123.6 (19.1) 124.7 (17.6) 0.515
Creatinine clearance, mean (SD), mL/mina 56.8 (23.1) 53.6 (21.9) 0.145
Duration of index admission, mean (SD), days 9.1 (7.9) 8.3 (7.2) 0.302
Drugs, mean (SD), number 8.3 (3.6) 8.4 (3.6) 0.622
Type of living, no. (%) 0.369
Living at home 158 (73) 146 (69)
Nursing home 59 (27) 66 (31)
Dementia subtype, no. (%)
Alzheimers disease 68 (31) 64 (30) 0.797
Vascular dementia 30 (14) 42 (20) 0.097
Other or unspecified dementia 119 (55) 106 (50) 0.316
MMSE, mean (SD)b 20.1 (4.3) 19.6 (4.8) 0.537
Medical history, no. (%)
Heart failure 54 (25) 72 (34) 0.039
Hypertension 105 (48) 116 (55) 0.190
Cardiac arrhythmia 58 (27) 62 (29) 0.561
Diabetes mellitus 47 (22) 61 (29) 0.090
Chronic obstructive pulmonary disease 18 (8) 16 (8) 0.774
Malignant disease, past or present 20 (9) 27 (13) 0.243
Myocardial infarction, past 25 (12) 36 (17) 0.105
Stroke, past 46 (21) 50 (24) 0.533
Figures are numbers of participants (percentage) unless stated otherwise
MMSE mini mental state examination, Hb hemoglobin
a Creatinine clearance was estimated from plasma creatinine values using the Cockcroft-Gault equation
bData missing for 154 patients in the control group and 119 patients in the intervention group
Table 2 Outcomes at 30- and






Drug-related readmissions, no. 68 58 0.32
Certain (no. of individual patientsa) 3 (3) 3 (3)
Probable (no. of individual patientsa) 25 (22) 24 (16)
Possible (no. of individual patientsa) 40 (25) 31 (23)
Patients readmitted because of DRP, no. (%) 50 (23) 40 (19) 0.29
Patients readmitted because of DRP within 30 days, no. (%) 24 (11) 11 (5) 0.03
Readmissions all causes
Patients readmitted, no. (%) 88 (41) 81 (38) 0.62
Readmissions, no. 141 138 0.62
Patients readmitted within 30 days, no. (%) 40 (18) 31 (15) 0.29
Mortality
Patients deceased 34 (16%) 44 (21%) 0.17
DRP drug-related problems
a The same person might have more than one type of drug-related readmission
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failure (HR 1.16, 95%CI 0.63–2.15, p = 0.64). Inclusion of heart
failureasaconfounderandaninteractiontermbetweenheart failure
and the intervention in a multiple Cox regression model revealed
that after adjustment for heart failure, the intervention significantly
reduced the risk of drug-related readmissions (HR 0.49, 95% CI
0.27–0.90, p= 0.02).
Subgroup analyses among patients without heart failure were
performed. In this subgroup (140 intervention and 163 control),
the180-daydrug-related readmissionratewassignificantly lower
in the intervention group than that in the control group; 11% (15/
140) and20%(33/163), in the intervention and the control group,
respectively (p = 0.02) (Table 3). A Kaplan-Meier survival anal-
ysis showed that the time-to-drug-related readmission within
180 days was significantly longer in the intervention group than
that in the control group (171.2 (2.7) days vs 153.1 (4.5) days,
Mantel-Cox log rank test, p = 0.02) (Fig. 3).
Additional analyses of the risk of early readmissions
(≤30 days) were performed. We observed a significant differ-
ence in the frequency of DRP readmissions within 30 days
between the intervention group (5% (11/212)) and the control
groups (11% (24/217)), p = 0.03) in the total study population
(including patients with heart failure) (Table 2). Moreover,
Kaplan-Meier curve analyses revealed significant differ-
ences in time to drug-related readmission during the
first 30 days after discharge between the intervention
and the control group in the total study population
(29.1 (0.30) days vs 28.1 (0.43) days, Mantel-Cox log
rank test, p = 0.03) (Fig. 4) and among patients without
heart failure (29.5 (0.29) days vs 28.3 (0.49) days,
Mantel-Cox log rank test, p = 0.02) (Fig. 5). Further,
sensitivity analyses were done, using certain and probable
(but not possibly) drug-related readmissions. After adjust-
ment for heart failure as a potential confounder and an
interaction term, a multiple Cox regression analysis
showed no difference between the groups (HR = 0.46,
95% CI = 0.18–1.18, p = 0.10). In Appendix 1, the other
main analyses for certain and probable (but not possibly)
drug-related readmissions are presented.
Discussion
We found that the intervention did not significantly reduce the risk
of drug-related readmissions at 180 days of follow-up. However,
Table 3 Outcomes at 30- and








Drug-related readmissions, no. 46 23 0.03
Certain (no. of individual patientsa) 1 (1) 0 (0)
Probable (no. of individual patientsa) 13 (12) 7 (6)
Possible (no. of individual patientsa) 32 (20) 16 (10)
Patients readmitted because of DRP, no. (%) 33 (20) 15 (11) 0.02
Patients readmitted because of DRP within 30 days, no. (%) 15 (9) 4 (3) 0.02
Readmissions all causes
Patients readmitted, no. (%) 60 (37) 41 (29) 0.17
Readmissions, no. 92 66 0.17
Patients readmitted within 30 days, no. (%) 27 (17) 14 (10) 0.10
Mortality
Patients deceased, no. (%) 21 (13) 20 (14) 0.72
DRP drug-related problems
a The same person might have more than one type of drug-related readmission
Fig. 2 Kaplan-Meier plots for drug-related readmissions within 180 days
in the total sample. HR and CI according to univariable Cox regression
analysis and p value from log rank test
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after adjustment for heart failure, the intervention significantly re-
duced the risk and further, in a post-hoc analysis of early
readmissions, a significantly reduced risk of 30-day readmissions
due toDRPswas observed in the total sample (without adjustment
forheart failure).Therewerealso a lowernumberof all-causeearly
readmissions in the intervention group, but the difference between
the groups did not reach statistical significance. As sensitivity
analyses,mainanalyseswere repeatedusingonlycertainandprob-
able (but not possibly) drug-related readmissions. The results, as
presented in Appendix 1, were in general similar to the results
calculated for certain, probable, and possibly drug-related
readmissions concerning estimated hazard ratios, but did not reach
significance due to the lower number of readmissions and thereby
lack of power.
A recent systematic review concluded that medication re-
views performed by clinical pharmacists at hospitals may im-
prove patient outcome [16], although another review investi-
gating interventions performed by different health care profes-
sionals did not show effects on readmission and mortality
[18]. However, in this review, also type of intervention dif-
fered between the included studies [18]. One randomized con-
trolled study not included in the review mentioned above
demonstrated a significant reduction in all cause readmissions
and increased time to readmission among individuals aged
65 years and older [23]. Moreover, Gillespie et al. revealed a
significant reduction in drug-related readmissions among par-
ticipants aged 80 years and older [4]. In these two studies,
clinical pharmacists conducted comprehensive medication re-
views, in the same way as in the present study.
In our study, no effect of the pharmacist intervention was ob-
served in patients with concomitant heart failure. This contrasts
findings of a systematic review indicating that participation of a
pharmacist in a multidisciplinary heart failure team may reduce
the rate of all-cause and heart failure readmissions by almost one-
third [24]. However, patients in our study were cognitively im-
paired.Adherence tomedication is crucial for treatment of patients
with heart failure, [25] and some of the patients in our study were
Fig. 3 Kaplan-Meier plots for drug-related readmissions within 180 days
in the subgroup of people without heart failure. HR and CI according to
univariable Cox regression analysis and p value from log rank test
Fig. 5 Kaplan-Meier plots for drug-related readmissions within 30 days
in the subgroup of people without heart failure. HR and CI according to
univariable Cox regression analysis and p value from log rank test
Fig. 4 Kaplan-Meier plots for drug-related readmissions within 30 days
in the total sample. HR and CI according to univariable Cox regression
analysis and p value from log rank test
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readmittedparticularlybecauseofadherenceproblems.Mostof the
people livedathome,andmanypatientswereunable tounderstand
the need for liquid restrictions or diuretic dosing self-adjustments.
Moreover, some patients had not been taking their heart failure
medication at all.
Heart failure is a severe clinical condition with high risk of
exacerbations. Frequent readmissions for medication adjustments
may be a requisite for proper follow-up and need not necessarily
indicate poor quality of care [22]. Our finding that pharmacist par-
ticipationdidnot influence the readmission rate amongcognitively
impairedpatientswithheart failureshouldbeseenagainst theback-
ground of the severity of the condition. Nevertheless, according to
Koshmanetal. [24],participationofclinicalpharmacistscanstillbe
beneficial to thisgroup;however, themodeof interventionpossibly
needs tobe revised. Face-to-facemeetings between thepharmacist
and the patient could be important for adherence [4]. In a compre-
hensive approach, involvement of relatives in the patients’ drug
therapymay be necessary.
Still, 30-day readmission rates are increasingly being used as
an indicator of quality of care [26, 27]. Our finding that partic-
ipation of a pharmacist in a ward team may significantly reduce
the risk of early readmissions due to DRPs is important not only
in this context. Let alone the risk of hospital penalization in 30-
day readmissions [22], and the costs associated with avoidable
readmissions, hospitalized individuals also are at an increased
risk of worsening of the general health status and may develop
confusion or complications from immobility [28].
In the present study, the physicians followed the advice of the
clinicalpharmacists toahighdegree,82%.Thishighrate shouldbe
seen in the context that the three pharmacists performing the inter-
vention were already acknowledged by the healthcare teams and
had beenworking at thewards before the trial. Close collaboration
between thepharmacist and theprescriber iscrucial forasuccessful
intervention. [13, 29] A recent study from Denmark investigated
the impact ofmedication reviewsperformedby apharmacist and a
clinicalpharmacologist at anorthopedicwardwithoutbeingpartof
thehealthcare team.Here, theacceptance ratewasonlyabout18%,
and the intervention had no effect on clinical outcome [30].
In the present study, pharmacists had full access to medical
and laboratory records and the intervention comprised medi-
cation reconciliation, comprehensive medication reviews, and
communication of findings at ward rounds. The comprehen-
siveness of the medication review and feedback during ward
rounds may have contributed to the significant effect (post-
hoc and subgroup analyses) on readmission rates.
Limitations
The study has some limitations that should be considered. The
30-days readmission analysis was not pre-specified in the
study protocol. However, because of the increased use of 30-
day readmission as an indicator of quality of care, the outcome
was added as a post-hoc analysis after the study was started.
The clinical pharmacists engaged in this study were highly ex-
perienced and had beenworking for up to 8 years at the respective
wards in the present study. This, togetherwith the fact that patients
fromthe samewardswere randomized toboth the interventionand
the control group, may have caused a risk of contamination bias.
During the study period, the clinical pharmacists worked not only
withstudyparticipantsbutalsowithotherpatients in thewards.The
prescribing physician and the clinical pharmacist discussed DRPs
ofboth those in the interventiongroupand thosenot included in the
study,andit isnotunreasonable toassumethatafter thereviews, the
physicians might have transferred knowledge to the control pa-
tients. Therefore, it is possible that the intervention would have
hadahigherimpactif theclinicalpharmacistshadnotbeenworking
in the wards before the intervention, and if the intervention and
control patients were located in different wards. However, the de-
sign of the study reflects a real-life setting, and results indicate that
the interventionhadaneffecteven thoughthepharmacistsoriginal-
lyworked in the selectedwards.
We did not evaluate if the DRPs identified by the clinical
pharmacists were clinically relevant and significant. However,
based on the high acceptance rate (82%), it is reasonable to
assume that most of the DRPs were judged to be clinically
relevant by the physician in charge.
Another caveat is that the primary outcome parameter,
drug-related readmissions, is not an objective measure. To
compensate for this, and in order to capture all aspects of
DRPs, individuals with different professional backgrounds
were recruited for the independent consensus group, and all
members were unaware of treatment assignments. The rea-
sons for hospitalization are in many cases multifactorial, and
DRPs are often only one of several factors leading to admis-
sion. Most of the drug-related readmissions were classified as
possibly contributing to readmission, likely because of this.
In this study, the effects of pharmacist-led comprehensive
medication reviews were investigated. Whether or not the re-
sults would have been different if the medication reviews had
been performed by someone not being a clinical pharmacist
was not the scope of this specific study.
Conclusion
Comprehensive approaches and interdisciplinary collabora-
tion are needed to avoid unnecessary hospitalizations and ear-
ly readmissions among people with dementia. Participation of
clinical pharmacists in healthcare team conducting compre-
hensive medication reviews did not significantly reduce the
risk of drug-related readmissions in patients with dementia or
cognitive impairment; however, post-hoc and subgroup anal-
yses indicated significant effects favoring the intervention.
These findings need confirmation in future studies.
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